CD274 and neoplasm: In PD-L1+ patients (prevalence: 54%), median OS: 15.7 months with atezolizumab vs. 10.3 months with docetaxel (p = 0.0102); in PD-L1− patients, median OS: 12.6 vs. 8.9 months; PD-L1+ cutoff: ≥1% tumor or immune cells; Ventana SP142 PD-L1 assay